RT Journal Article
SR Electronic
T1 Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes
JF BMJ Open Diabetes Research & Care
JO BMJ Open Diab Res Care
FD American Diabetes Association
SP e002199
DO 10.1136/bmjdrc-2021-002199
VO 9
IS 1
A1 Lingwen Ying
A1 Chaohui Jian
A1 Xiaojing Ma
A1 Kun Ge
A1 Wei Zhu
A1 Yufei Wang
A1 Aihua Zhao
A1 Jian Zhou
A1 Wei Jia
A1 Yuqian Bao
YR 2021
UL http://drc.bmj.com/content/9/1/e002199.abstract
AB Introduction Saliva collection is a non-invasive test and is convenient. 1,5-anhydroglucitol (1,5-AG) is a new indicator reflecting short-term blood glucose levels. This study aimed to explore the relationship between saliva 1,5-AG and insulin secretion function and insulin sensitivity.Research design and methods Adult patients with type 2 diabetes who were hospitalized were enrolled. Based on blood glucose and C-peptide, homeostasis model assessment 2 for β cell secretion function, C-peptidogenic index (CGI), △2-hour C-peptide (2hCP)/△2-hour postprandial glucose (2hPG), ratio of 0–30 min area under the curve for C-peptide and area under the curve for glucose (AUCCP30/AUCPG30), and AUC2hCP/AUC2hPG were calculated to evaluate insulin secretion function, while indicators such as homeostasis model assessment 2 for insulin resistance were used to assess insulin sensitivity.Results We included 284 subjects (178 men and 106 women) with type 2 diabetes aged 20–70 years. The saliva 1,5-AG level was 0.133 (0.089–0.204) µg/mL. Spearman’s correlation analysis revealed a significantly negative correlation between saliva 1,5-AG and 0, 30, and 120 min blood glucose, glycated hemoglobin A1c, and glycated albumin (all p<0.05), and a significantly positive association between saliva 1,5-AG and CGI (r=0.171, p=0.004) and AUCCP30/AUCPG30 (r=0.174, p=0.003). The above correlations still existed after adjusting for age, sex, body mass index, and diabetes duration. In multiple linear regression, saliva 1,5-AG was an independent factor of CGI (standardized β=0.135, p=0.015) and AUCCP30/AUCPG30 (standardized β=0.110, p=0.020).Conclusions Saliva 1,5-AG was related to CGI and AUCCP30/AUCPG30 in patients with type 2 diabetes.Trial registration number ChiCTR-SOC-17011356.Data are available on reasonable request. The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.